|Bid||16.41 x 1800|
|Ask||18.50 x 1000|
|Day's Range||16.63 - 17.60|
|52 Week Range||11.50 - 50.00|
|Beta (3Y Monthly)||1.88|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 30, 2019 - Aug 5, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||30.20|
Quality-adjusted progression free survival and quality-adjusted time without cancer related symptoms or toxicity demonstrate the benefit of Rubraca maintenance t
Accepted abstracts highlight additional data from phase 3 ARIEL3 clinical trial, genomic data from phase 2 TRITON2 clinical trial, and the designs of other ongoing rucaparib trials
Clovis (CLVS) delivered earnings and revenue surprises of 9.44% and 4.53%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
The Boulder, Colorado-based company said it had a loss of $1.63 per share. The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for ...
Clovis Oncology Inc NASDAQ/NGS:CLVSView full report here! Summary * Bearish sentiment is moderate and declining * Economic output in this company's sector is expanding Bearish sentimentShort interest | NeutralShort interest is moderately high for CLVS with between 10 and 15% of shares outstanding currently on loan. However, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on April 12. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding CLVS are favorable, with net inflows of $3.04 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
BOULDER, Colo.-- -- $33.1M in Rubraca ® global sales for the first quarter of 2018 Updated data on 52 patients with BRCA-mutant mCRPC provided to FDA; RECIST response rate highly consistent with that shown at ESMO 2018 Targeting late 2019 for supplemental NDA filing for BRCA-mutant advanced prostate cancer; data update expected at Fall 2019 medical meeting Clovis-sponsored combination studies of lucitanib ...
During Soleno Therapeutics' (SLNO) Q1 conference call, investor focus will be on its progress with the ongoing study on DCCR tablets, developed for the treatment of Prader-Willi syndrome.
Perrigo (PRGO) is focused on Consumer Healthcare Americas segment. Let's see if it aids the company's results in the soon-to-be reported quarter.
Investors will focus on Cronos' (CRON) regular top and bottom-line numbers along with its pipeline progress when the company reports Q1 results.
Clovis Oncology, Inc. (CLVS) today announced that Patrick J. Mahaffy, Chief Executive Officer and President, will present at the Bank of America Merrill Lynch Healthcare Conference 2019 on Tuesday, May 14, 2019 at 2:20 PM Pacific Time. Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. Clovis Oncology targets development programs at specific subsets of cancer populations, and simultaneously develops, with partners, for those indications that require them, diagnostic tools intended to direct a compound in development to the population that is most likely to benefit from its use.
"October lived up to its scary reputation—the S&P 500 falling in the month by the largest amount in the last 40 years, the only worse Octobers being '08 and the Crash of '87\. For perspective, there have been only 5 occasions in those 40 years when the S&P 500 declined by greater than 20% from […]
Clovis Oncology, Inc. (CLVS) today announced that it has entered into an agreement for up to $175 million in non-dilutive clinical trial financing with certain affiliates of TPG Sixth Street Partners to reimburse Clovis’ costs and expenses related to the ATHENA clinical trial. ATHENA is Clovis Oncology’s largest clinical trial, with a planned target enrollment of 1000 patients across more than 270 sites in at least 25 countries.
Clovis (CLVS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The latest earnings announcement Clovis Oncology, Inc. (NASDAQ:CLVS) released in December 2018 showed company earnings became less negative compared to the previous year's level as a result of recent...
Clovis Oncology, Inc. will announce its first quarter 2019 financial results on Tuesday, May 7, 2019, before the open of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast at 8:30 a.m.
Although sales of Clovis' (CLVS) Rubraca improved in the fourth quarter of 2018, the drug may face significant competition going forward. Clovis is also evaluating Rubrca for other cancer indications.
In the latest Clovis Oncology (NASDAQ:CLVS), the company's stock took a major hit as one of its trials for a drug designed to treat cancer has been halted suddenly.The Boulder, Colorado-brand said on Friday that it would no longer continue the phase two trial of its rucaparib treatment that was designed to help patients with bladder cancer, a report close to the matter said. The company decided to stop the trial after a recommendation from an independent monitoring committee was sent its way, the Dow Jones said.Clovis Oncology added that the committee recommendation was not the result of a "safety profile" of the treatment, Dow Jones added. CLVS stock was down roughly 14% after the bell on Friday following the company's announcement.InvestorPlace - Stock Market News, Stock Advice & Trading TipsShares then fell about 11.9% on Monday, sending the price of its stock to now be at $20.69 per share. At the beginning of the year, the stock was trading at $19.39 per share, which means that it has still managed to increase by about 6.7% throughout 2019.Clovis Oncology was founded about 10 years ago in the aforementioned mountain town, where it is currently headquartered. It is listed in the NASDAQ Biotechnology Index and it has several products in its product pipeline.These include rociletinib, which is designed to treat non-small cell lung cancer, with a phase III trial of the drug completed in April 2016. Rucaparib is designed to treat ovarian cancer, while lucitanib treats advanced solid tumors. More From InvestorPlace * 7 Marijuana Companies: Which Pot Stocks Should You Buy? * 7 AI Stocks to Watch with Strong Long-Term Narratives * 10 Dow Jones Stocks Holding the Blue Chip Index Back Compare Brokers The post Clovis Oncology News: CLVS Stock Sinks on Trial for Cancer Treatment appeared first on InvestorPlace.
Clovis Oncology (CLVS) halts mid-stage bladder cancer study evaluating Rubraca monotherapy. It is unlikely to provide meaningful clinical benefit as reviewed by an independent data monitoring committee.